Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 vs investigator's choice in HER2 IHC3+ metastatic colorectal cancer after standard therapy failure
CTR20260191Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in colorectal cancer (CRC), sponsored by Nanjing Shunxin Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
TQB2102
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260191.